916 related articles for article (PubMed ID: 36066519)
1. Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System.
Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Peralta C; Neilands TB; Garcia PK; Muiru A; Karliner L; Shlipak MG; Estrella MM
JAMA; 2022 Sep; 328(9):861-871. PubMed ID: 36066519
[TBL] [Abstract][Full Text] [Related]
2. Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
Rodriguez LA; Finertie H; Neugebauer RS; Gosiker B; Thomas TW; Karter AJ; Gilliam LK; Oshiro C; An J; Simonson G; Cassidy-Bushrow AE; Dombrowski S; Nolan M; O'Connor PJ; Schmittdiel JA
Lancet Reg Health Am; 2024 Jun; 34():100759. PubMed ID: 38745886
[TBL] [Abstract][Full Text] [Related]
3. Geographic variation and racial disparities in adoption of newer glucose-lowering drugs with cardiovascular benefits among US Medicare beneficiaries with type 2 diabetes.
Chen WH; Li Y; Yang L; Allen JM; Shao H; Donahoo WT; Billelo L; Hu X; Shenkman EA; Bian J; Smith SM; Guo J
PLoS One; 2024; 19(1):e0297208. PubMed ID: 38285682
[TBL] [Abstract][Full Text] [Related]
4. Are There Differences in Postoperative Opioid Prescribing Across Racial and Ethnic Groups? Assessment of an Academic Health System.
O'Sullivan LR; Shofer FS; Delgado MK; Agarwal AK; Humbyrd C
Clin Orthop Relat Res; 2023 Aug; 481(8):1504-1511. PubMed ID: 36795497
[TBL] [Abstract][Full Text] [Related]
5. Prescription Patterns of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients with Coronary Artery Disease.
Hofer F; Kazem N; Schweitzer R; Hammer A; Jakse F; Koller L; Hengstenberg C; Sulzgruber P; Niessner A
Cardiovasc Drugs Ther; 2021 Dec; 35(6):1161-1170. PubMed ID: 33666822
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Diabetes Medications Used by Adults With Commercial Insurance vs Medicare Advantage, 2016 to 2019.
McCoy RG; Van Houten HK; Deng Y; Mandic PK; Ross JS; Montori VM; Shah ND
JAMA Netw Open; 2021 Feb; 4(2):e2035792. PubMed ID: 33523188
[TBL] [Abstract][Full Text] [Related]
7. Use of Sodium-Glucose Cotransporter 2 Inhibitors and Glucagonlike Peptide-1 Receptor Agonists in Patients With Diabetes and Cardiovascular Disease in Community Practice.
Nanna MG; Kolkailah AA; Page C; Peterson ED; Navar AM
JAMA Cardiol; 2023 Jan; 8(1):89-95. PubMed ID: 36322056
[TBL] [Abstract][Full Text] [Related]
8. Racial/Ethnic Disparities in the Performance of Prediction Models for Death by Suicide After Mental Health Visits.
Coley RY; Johnson E; Simon GE; Cruz M; Shortreed SM
JAMA Psychiatry; 2021 Jul; 78(7):726-734. PubMed ID: 33909019
[TBL] [Abstract][Full Text] [Related]
9. Association of Prescription Co-payment With Adherence to Glucagon-Like Peptide-1 Receptor Agonist and Sodium-Glucose Cotransporter-2 Inhibitor Therapies in Patients With Heart Failure and Diabetes.
Essien UR; Singh B; Swabe G; Johnson AE; Eberly LA; Wadhera RK; Breathett K; Vaduganathan M; Magnani JW
JAMA Netw Open; 2023 Jun; 6(6):e2316290. PubMed ID: 37261826
[TBL] [Abstract][Full Text] [Related]
10. Utilization Rates of SGLT2 Inhibitors and GLP-1 Receptor Agonists and Their Facility-Level Variation Among Patients With Atherosclerotic Cardiovascular Disease and Type 2 Diabetes: Insights From the Department of Veterans Affairs.
Mahtta D; Ramsey DJ; Lee MT; Chen L; Al Rifai M; Akeroyd JM; Vaughan EM; Matheny ME; Santo KRDE; Navaneethan SD; Lavie CJ; Birnbaum Y; Ballantyne CM; Petersen LA; Virani SS
Diabetes Care; 2022 Feb; 45(2):372-380. PubMed ID: 35015080
[TBL] [Abstract][Full Text] [Related]
11. Racial inequities in U.S. naloxone prescriptions.
Madden EF; Qeadan F
Subst Abus; 2020; 41(2):232-244. PubMed ID: 31718487
[No Abstract] [Full Text] [Related]
12. State Variation in Racial and Ethnic Disparities in Incidence of Triple-Negative Breast Cancer Among US Women.
Sung H; Wiese D; Jatoi I; Jemal A
JAMA Oncol; 2023 May; 9(5):700-704. PubMed ID: 36862439
[TBL] [Abstract][Full Text] [Related]
13. The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.
Korayem GB; Alshaya OA; Alghamdi AA; Alanazi SS; Almutib RT; Alsaileek M; Alrashidi A; Aldosari N; Bin Sheraim N; Al Yami MS; Almohammed OA
Front Public Health; 2022; 10():1031306. PubMed ID: 36408008
[TBL] [Abstract][Full Text] [Related]
14. Prescription Patterns of Cardiovascular- and Kidney-Protective Therapies Among Patients With Type 2 Diabetes and Chronic Kidney Disease.
Lamprea-Montealegre JA; Madden E; Tummalapalli SL; Chu CD; Peralta CA; Du Y; Singh R; Kong SX; Tuot DS; Shlipak MG; Estrella MM
Diabetes Care; 2022 Dec; 45(12):2900-2906. PubMed ID: 36156061
[TBL] [Abstract][Full Text] [Related]
15. Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus.
Zhang J; Van Spall HG; Li L; Khan MS; Pandey A; Thabane L; Bai X; Wang Y; Lip GY; Li G
Diabetes Metab Syndr; 2023 Jul; 17(7):102804. PubMed ID: 37315473
[TBL] [Abstract][Full Text] [Related]
16. Racial, Ethnic, and Socioeconomic Inequities in Glucagon-Like Peptide-1 Receptor Agonist Use Among Patients With Diabetes in the US.
Eberly LA; Yang L; Essien UR; Eneanya ND; Julien HM; Luo J; Nathan AS; Khatana SAM; Dayoub EJ; Fanaroff AC; Giri J; Groeneveld PW; Adusumalli S
JAMA Health Forum; 2021 Dec; 2(12):e214182. PubMed ID: 35977298
[TBL] [Abstract][Full Text] [Related]
17. Association of Race and Ethnicity With Initial Prescription of Antiretroviral Therapy Among People With HIV in the US.
Zalla LC; Cole SR; Eron JJ; Adimora AA; Vines AI; Althoff KN; Silverberg MJ; Horberg MA; Marconi VC; Coburn SB; Lang R; Williams EC; Gill MJ; Gebo KA; Klein M; Sterling TR; Rebeiro PF; Mayor AM; Moore RD; Edwards JK
JAMA; 2023 Jan; 329(1):52-62. PubMed ID: 36594946
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Prescribing in Patients With Diabetes Mellitus With and Without Cardiovascular Disease.
Gay HC; Yu J; Persell SD; Linder JA; Srivastava A; Isakova T; Huffman MD; Khan SS; Mutharasan RK; Petito LC; Feinstein MJ; Shah SJ; Yancy CW; Kho AN; Ahmad FS
Am J Cardiol; 2023 Feb; 189():121-130. PubMed ID: 36424193
[TBL] [Abstract][Full Text] [Related]
19. National Trends in Use of Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-like Peptide-1 Receptor Agonists by Cardiologists and Other Specialties, 2015 to 2020.
Adhikari R; Jha K; Dardari Z; Heyward J; Blumenthal RS; Eckel RH; Alexander GC; Blaha MJ
J Am Heart Assoc; 2022 May; 11(9):e023811. PubMed ID: 35475341
[TBL] [Abstract][Full Text] [Related]
20. Decision Algorithm for Prescribing SGLT2 Inhibitors and GLP-1 Receptor Agonists for Diabetic Kidney Disease.
Li J; Albajrami O; Zhuo M; Hawley CE; Paik JM
Clin J Am Soc Nephrol; 2020 Nov; 15(11):1678-1688. PubMed ID: 32518100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
